Patents Assigned to Fundacio Privada Institut d'Investigacio Oncologica de Vall Hebron
  • Micropeptides and uses thereof
    Patent number: 11858972
    Abstract: The present invention relates to new peptidic compounds, more specifically to micropeptides derived from lncRNAs implicated in cancer and cellular plasticity. It also relates to the use of the said micropeptides in the treatment of proliferative diseases, more specifically in the treatment of cancer.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: January 2, 2024
    Assignee: Fundació Privada Institut d'Investigació Oncològica de Vall Hebron
    Inventors: Maria Abad Méndez, Olga Boix Sánchez, Emanuela Greco, Iñaki Merino Valverde
  • Methods and compositions for the treatment of cancer
    Patent number: 11427621
    Abstract: The invention relates to a polypeptide comprising or consisting of the polypeptide of SEQ ID NO: 1 wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine, or a functionally equivalent variant of said polypeptide wherein the residue X at position 89 of SEQ ID NO: 1 is not a cysteine and their use in medicine, particularly in the prevention and/or treatment of cancer.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: August 30, 2022
    Assignees: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL HEBRON
    Inventors: Laura Soucek, Toni Jauset González, Marie-Eve Beaulieu
  • Antibodies against LIF and uses thereof
    Patent number: 10583191
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: March 10, 2020
    Assignees: MOSAIC BIOMEDICALS SLU, FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÓGICA DE VALL HEBRON, FUNDACIÓ PRIVADA INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira
  • Methods and compositions for the treatment of cancer
    Patent number: 10370434
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: August 6, 2019
    Assignee: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON
    Inventors: Laura Soucek, Marie-Eve Beaulieu
  • Antibodies against LIF and uses thereof
    Patent number: 10206999
    Abstract: Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 19, 2019
    Assignees: Mosaic Biomedicals, S.L., Fundació Privada Institut d'Investigació Oncológica de Vall Hebron, Fundació Privada Institució Catalana de Recerca | Estudis Avançats
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
    Publication number: 20160122415
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Application
    Filed: May 7, 2014
    Publication date: May 5, 2016
    Applicant: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (FPIIOVH)
    Inventors: Laura SOUCEK, Marie-Eve BEAULIEU
  • Method for diagnosing cancers expressing the HER2 receptor or its truncated variants
    Patent number: 8389227
    Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognizes an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: March 5, 2013
    Assignees: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recera I Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall Hebron
    Inventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres
  • Method for Diagnosing Cancers Expressing the HER2 Receptor or its Truncated Variants
    Publication number: 20090311262
    Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognises an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2. The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.
    Type: Application
    Filed: June 5, 2009
    Publication date: December 17, 2009
    Applicants: Fundacio Privada Institut de Recerca Hospital Universitari Vall Hebron, Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de Vall Hebron
    Inventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Liuis Parra Palau, Sirle Laos, Jose Baselga Torres